Letzel H, Bluemner E
STATICON, Medizinische Forschungsgesellschaft, Planegg, West Germany.
J Hypertens Suppl. 1990 Sep;8(4):S83-6.
We studied the dose-response relationship for hydrochlorothiazide + triameterene and verapamil, comparing monotherapy with combined treatment in 216 hypertensive patients over 3 weeks of active treatment following a 2-week washout period with placebo. The study was a double-blind, randomly allocated, clinical trial using a two-factorial analysis of variance design. The results showed that the highest dose (a combination of 160 mg verapamil with 25 mg hydrochlorothiazide and 50 mg triameterene) also had the maximum antihypertensive effect. We further conclude that multifactorial trial designs are the most useful designs for analyzing the effects of combination therapy and therefore should be used more often.
我们研究了氢氯噻嗪+氨苯蝶啶与维拉帕米的剂量反应关系，在216名高血压患者中，经过2周安慰剂洗脱期后，进行了3周积极治疗，比较了单一疗法与联合治疗。该研究是一项采用双因素方差分析设计的双盲、随机分配的临床试验。结果显示，最高剂量（160 mg维拉帕米与25 mg氢氯噻嗪和50 mg氨苯蝶啶的组合）也具有最大的降压效果。我们进一步得出结论，多因素试验设计是分析联合治疗效果最有用的设计，因此应更频繁地使用。
